Transcriptional silencing of the Wnt-Antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Kocemba, Kinga A ^a   Groen, Richard W J ^a   van Andel, Harmen ^a   Kersten, Marie José ^a   Mahtouk, Karène ^a   Spaargaren, Marcel ^a   Pals, Steven T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; AZACITIDINE; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE; WNT PROTEIN;

ADVANCED CANCER; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DOWN REGULATION; GENE FUNCTION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; MULTIPLE MYELOMA; PRIMARY TUMOR; PROMOTER REGION; WNT SIGNALING PATHWAY; BONE MARROW; DISEASE COURSE; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

AZACITIDINE; BASE SEQUENCE; BONE MARROW; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA METHYLATION; GENE SILENCING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84857155905     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030359     Document Type: Article

References (59)

1. Podar K, Chauhan D, Anderson KC, (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23: 10-24.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC, (2009) Multiple myeloma. Lancet 374: 324-329.
3. Edwards CM, Zhuang J, Mundy GR, (2008) The pathogenesis of the bone disease of multiple myeloma. Bone 42: 1007-1013.
4. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, et al. (2007) Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 67: 7665-7674.
5. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, et al. (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106: 3160-3165.
6. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
7. Malhotra S, Kincade PW, (2009) Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell 4: 27-36.
8. Staal FJ, Clevers HC, (2005) WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol 5: 21-30.
9. Staal FJ, Sen JM, (2008) The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis. Eur J Immunol 38: 1788-1794.
10. van de Wetering M, Cavallo R, Dooijes D, van Beest M, van Es J, et al. (1997) Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88: 789-799.
11. Kawano Y, Kypta R, (2003) Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116: 2627-2634.
12. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, et al. (2004) Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 101: 6122-6127.
13. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, et al. (2009) Aurora kinase A is a target of Wnt/{beta}-catenin involved in multiple myeloma disease progression. Blood 114: 2699-2708.
14. Haaber J, Abildgaard N, Knudsen LM, Dahl IM, Lodahl M, et al. (2008) Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 140: 25-35.
15. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, et al. (2009) The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113: 517-525.
16. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr, (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42: 669-680.
17. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, et al. (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112: 196-207.
18. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, et al. (2005) FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. Embo J 24: 73-84.
19. Lescher B, Haenig B, Kispert A, (1998) sFRP-2 is a target of the Wnt-4 signaling pathway in the developing metanephric kidney. Dev Dyn 213: 440-451.
20. Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, et al. (2004) DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 23: 8520-8526.
21. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, et al. (2007) Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109: 1692-1700.
22. Groen RW, Oud ME, Schilder-Tol EJ, Overdijk MB, ten Berge D, et al. (2008) Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 68: 6969-6977.
23. Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, et al. (2006) Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25: 4116-4121.
24. Dosen G, Tenstad E, Nygren MK, Stubberud H, Funderud S, et al. (2006) Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC immunology 7: 13-30.
25. Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, et al. (2010) Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 10: 198-216.
26. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, et al. (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435: 1126-1130.
27. Qiang YW, Endo Y, Rubin JS, Rudikoff S, (2003) Wnt signaling in B-cell neoplasia. Oncogene 22: 1536-1545.
28. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, et al. (2005) Wnts induce migration and invasion of myeloma plasma cells. Blood 106: 1786-1793.
29. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET, (2005) Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65: 7554-7560.
30. Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, et al. (2007) Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 28: 2459-2466.
31. Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, et al. (2008) Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98: 1147-1156.
32. Suzuki R, Onizuka M, Kojima M, Shimada M, Fukagawa S, et al. (2007) Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia. Br J Haematol 138: 624-631.
33. Vibhakar R, Foltz G, Yoon JG, Field L, Lee H, et al. (2007) Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Neuro Oncol 9: 135-144.
34. Timm A, Grosschedl R, (2005) Wnt signaling in lymphopoiesis. Curr Top Microbiol Immunol 290: 225-252.
35. Clevers H, (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
36. Polakis P, (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851.
37. Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, et al. (2009) Beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 15: 2731-2738.
38. Schmidt M, Sievers E, Endo T, Lu D, Carson D, et al. (2009) Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 144: 796-798.
39. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, et al. (2007) Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A 104: 7516-7521.
40. Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, et al. (2001) Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 11: 951-961.
41. Lewis SL, Khoo PL, De Young RA, Steiner K, Wilcock C, et al. (2008) Dkk1 and Wnt3 interact to control head morphogenesis in the mouse. Development 135: 1791-1801.
42. Sick S, Reinker S, Timmer J, Schlake T, (2006) WNT and DKK determine hair follicle spacing through a reaction-diffusion mechanism. Science 314: 1447-1450.
43. Yamaguchi Y, Passeron T, Hoashi T, Watabe H, Rouzaud F, et al. (2008) Dickkopf 1 (DKK1) regulates skin pigmentation and thickness by affecting Wnt/beta-catenin signaling in keratinocytes. Faseb J 22: 1009-1020.
44. Egger G, Liang G, Aparicio A, Jones PA, (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
45. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, et al. (2002) Cancer epigenetics and methylation. Science 297: 1807-1808.
46. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM, (2003) Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A 100: 12253-12258.
47. Herman JG, (2005) Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol 70: 329-333.
48. Klein G, (2005) Epigenetics: surveillance team against cancer. Nature 434: 150.
49. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, et al. (2007) 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 6: 1718-1727.
50. Chim CS, Pang R, Fung TK, Choi CL, Liang R, (2007) Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 21: 2527-2536.
51. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, et al. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73: 517-526.
52. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, et al. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484-2491.
53. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, et al. (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99: 1405-1410.
54. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, et al. (2004) VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 104: 2886-2892.
55. Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, et al. (2007) HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109: 3024-3030.
56. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, et al. (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106-2111.
57. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, et al. (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371-379.
58. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, et al. (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24: 425-436.
59. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, et al. (2008) Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842.